Cardiac rehabilitation

Fahriye Vatansever Ağca®

Department of Cardiology, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey

DOI: 10.18621/eurj.414958

ABSTRACT

Cardiovascular diseases are one of the majorcause of mortality globally. Coronary heart disease is the largest subset of cardiovascular disease. Although mortality rates decline during time, hospital discharge data as a measure of morbidity rates are stable, leading to larger pool of patients eligible to benefit from cardiac rehabilitation. Cardiac rehabilitation is a multi-disciplinary approach including exersize training, patient counselling, education and nutritional guidance. Despite the many known benefits of cardiac rehabilitation, refferal and participation rates remainlow and interventions to increase its use need to be developed.

Keywords: Coronary, rehabilitation, exercise

Received: April 13, 2018; Accepted: August 19, 2018; Published Online: January 10, 2019

C oronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide with annual mortality over 17 million people. It is expected that, more than 80 million individuals will be diagnosed with cardiovscular disease by 2030 worldwide [1, 2]. The increasing prevalence of CHD is due to the many risk factors that are becoming more endemic (type 2 diabetes mellitus [T2DM], obesity, sedentary lifestyle, hypertension [HTN]) and aging of the population [2].

While cardiovascular diseases' (CVD) mortality are decreasing, by improved emergency response and early intervention, medical and surgical management and to a lesser degree and risk factor reduction, it is still an important cause of disability around the world. Hospital discharge data as a measure of morbidity has been relatively stable since 2004 [3-5]. The percentage of years lived with disability has increased by 25% globally since 2005 [6].

Individuals with CVD are at high risk for subsequent major cardiac events and death [7], thus secondary prevention is very important. The impact of CVD are, increase in morbidity and mortality and the disturbing effects of secondary disability, decreased quality of life, and elevated health and social costs [8]. Cardiovascular rehabilitation (CR) is an effective and low-cost model of care for secondary prevention of CVD. It is an outpatient chronic diseasemanagement program, delivering the core components of assessment, medical risk factormanagement, structured exercise training (ET), patient educationas well as psychosocial and behavioral counselling [9].

CR consists of three phases. Phase I refers to inpatient rehabilitation during the index hospitalization. Due to the shortening durations of hospital stay, phase I CR has become less formalized. Phase II refers to physician supervised, outpatient monitored physical activity during the 2-16 weeks after discharge. Patients usually undergo up to 36 sessions in anexercise program. After this phase, patients may continue into phase III, which is an unmonitored exercise program. CR programs additionally provide nutritional, psycho-



Address for correspondence: Fahriye Vatansever Ağca, MD., Associate Professor, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Cardiology, Bursa, Turkey E-mail: drfahriyevatansever@yahoo.com

Copyright © 2019 by The Association of Health Research & Strategy Available at http://dergipark.gov.tr/eurj logical and smoking cessation counseling, besides lipid and blood pressure management.

Indications, Contraindications and Attendance

Most patients reffered for CR are eligible to participate. Common indications for CR are acute coronary syndrome, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), valve surgery, and chronic stable heart failure with reduced ejection fraction (HFrEF) (Table 1) [11-13]. HF is a relatively new addition, as there were long-standing concerns that exercise therapy (ET) would exacerbate HF. However, more recent studies by Wisløff et al. [14] and others [15] have shown that ET can elicit beneficial peripheral metabolic adaptations in patients with HF, resulting in a paradigm shift in favor of structured ET as a therapy for HF patients. The American Heart Association (AHA) and American College of Cardiology (ACC) decide CR is a Class I indication for these conditions. Contraindications for CR are listed in Table 2 [16]. The other preclusive reasons of participation include musculoskeletal problems, severe illnesses, co-morbid diseases, acute infections and inflammatory states that limit ET.

Despite favorable data and Class I recommendations, less than 30% of eligible CHD patients participate in CR programme. Commonly, referrals for these programs are not usually the part of routine daily care for many physicians. Frequently, access to facilities is difficult in rural areas. The other reason may be the significant advances in both medical and revascularization therapies, which have seen faster adoption by

Table 1. Indications for CR

Acute myocardial infarction Stable angina pectoris Coronary artery bypass graft surgery Heart valve repair or replacement surgery Heart valve repair or replacement surgery Percutaneous transluminal coronary angioplasty Chronic congestive heart failure Peripheral arterial disease Heart transplantation Heart-lung transplantation CR = cardiac rehabilitation

Table 2. Contraindications for CR

| Unstable angina |
|---------------------------------------|
| Severe or symptomatic aortic stenosis |
| Decompensated HF |
| Severe obstructive cardiomyopathy |
| Acute cardiac mural thrombus |
| Acute deep venous thrombus |
| Pulmonary embolism |
| CR = cardiac rehabilitation |

the cardiologists, because of a combination of physician reimbursement and marketing by pharmaceutical and device companies. Although CHD is a major cause of morbidity and mortality, interest in conventional and alternative approaches to the delivery of CR has grown and adoption is increasing [17, 18]. Decreased attendance of patients has been noted especially among women, non-whites, the elderly, the rural population, and individuals with low socio-economic status [19]. Additionally, the existence of comorbidities such as higher body mass index, poor functional capacity and exercise habits, tobacco use, and depression before starting CR has been associated with lower attendance and higher dropout rates from CR programs [20, 21]. Strong recommendation from primary care physicians and CVD specialists plays a critical role in patient participation and adherence to CR programs, and helps the patient understand the value of this treatment option [22, 23]. Patients adviced to see a cardiologist or a cardiac surgeon at the time of hospital discharge had > 2-fold higher odds of being referred to CR when compared to patients adviced to see with a family physician (p < 0.05) [24]. The other fact is that, only 40%-60% of patients referred to these programs complete the prescribed course of CR [25].

Exercise Modes and Intensity

The exercise prescription therapy starts with a symptom limited, exercise tolerance test. Thereafter, workouts typically consist of a short warm up period, followed by supervised individualized aerobic exercise, and a short cool down phase. The aerobic exercise includes a 20-60 min workouts 3-5 days a week at 50-80% of maximal exercise capacity [26]. Relatively recent data suggest that high intensity interval training (HIIT) produces larger and more rapid in-

creases in exercise capacity [14, 27, 28]. Weston et al. [29] have studied ET intensity and in reviewed a collection of meta-analysis data of 1468 patients enrolled in high versus moderate intensity protocols, and conclude that the benefits of HIIT in improving cardiorespiratory fitness (CRF) exceed those gained from moderate intensity continuous training (MICT) protocols utilized as the current standard of care for CR. In a study comparing moderate intensity continuous training MICT and HIIT protocols in patients with stable ischemic cordiomyopathy demonstrated a significant increase in peak oxygen consumption (VO2MAX) in the HIIT group [30]. HIIT also improved endothelial functions, reversed left ventricular remodelling and increased ejection fraction more than continous training. Similar superior improvements have been noted in other studies too [14, 27, 28]. The differentiating factors between HIIT and MICT; that usual therapy involves continuous maintenance of workload at an intensity of 50%-65% of the peak, often measured as VO2MAX or peak HR. HIIT protocols consist of shorter high-intensity intervals (75%-95% of maximal effort) interrupted by periods of rest [31]. In a similar comparative meta-analysis including 277 patients with CHD, Elliot et al. [32] and colleagues demonstrated that HIIT was associated with a significantly higher VO2, which is independently associated with reduced CVD mortality.

PREhabilitation is a new approach to ET-based therapy which is suggested to optimize post-CABG outcomes. The CR programme starts pre-operatively, that is, before bypass surgery, to decrease post-CABG morbidity and mortality. In a study, implementing preoperative ET led to improved performance on a 6minute walk test, a shorter hospital stay, fewer pulmonary complications, and a significantly lower incidence of postoperative atrial fibrillation [33].

Additionally to ET intensity, frequency and optimal "dosing" of ET also play an important role. Michaelides *et al.* [34] found that 30 min of ET increased vascular elasticity and improved antioxidant balance; however, these benefits were lost when the ET duration was extended to 60 min. Recent data suggest that when applied to vigorous ET, more moderate amounts of ET may provide added benefits at reduced risk (< 5 h of ET per week) [35, 36]. These physiologic findings supported by a cohort study of near 13,000 patients conducted by Blair *et al.* [37]. It was found that a plateau in benefits above 9-10 metabolic equivalents (MET) above which adjusted all-cause mortality no longer improved [37]. Similarly, increases above levels of moderate ET frequency in women were not associated with reductions in the risk of vascular diseases in a prospective study of women in the United Kingdom [38]. These findings support the 2013 ACC/AHA recommendations for reducing CVD risk; 150 minutes of weekly moderate intensity exercise or 75 minutes of vigorous aerobic activity weekly in conjunction with moderate-to-high intensity muscle strengthening exercises twice per week [16].

Effects of Exercise Training on Cardiovascular Physiology

Regular physical activity (PA) has multiple effects on health, including improved endothelial function, increased maximal aerobic capacity with better oxidative efficiency, and higher anti-oxidant activity. These physiological changes are the causes of improvements in both diastolic dysfunction and contractility, lower resting blood pressure (BP) and HR, increased muscle mass and even better cognitive performance. Increased metabolic demands during ET cause upregulation of mitochondrial division and modify energy pathways within the organelles [31]. Increased mitochondrial content in muscle promotes fat oxidation especially on carbohydrate oxidation [39]. This adaptation decreases lactate as a byproduct and leads to longer duration of ET at increased aerobic capacity [40]. Additionally, ET favorably impacts cardiac remodeling and results in improvements of the performance of the myocard [41]. The mechanisms are; reversal of metabolic decoupling processes with decreases in glucose uptake in patients with metabolic syndrome and postulation of angiogenesis in working muscles mediated by βadrenergic stimulation of capillary growth by vascular endothelial growth factors and platelet-derived growth factors [42-44]. More recent studies have shown that ET-associated post-transcriptional gene regulation via micro-RNA reduce remodeling through interactions among metabolic, contractile and epigenetic genes [45]. ET modifies sympathovagal signaling results in an increase in parasympathetic tone, leading to increased HR variability which confers a better prognosis [46, 47]. Accordingly, ET increases the threshold for ventricular ectopic activity, and controlled trials have shown that ectopic beats are less common in

trained than untrained post-MI patients [48]. Via alterations in systemic vasoconstriction, sodium and water retention, angiotensinogen II modulation, aldosterone production and decreasing aldosterone lowers sympathetic tone, complementing the effect of other ET-induced modulators of parasympathetic activity [46, 49]. The other mechanism for regulation of sympathetic tone is via adrenomodullin and atrio/brain-natriureticpeptides which are related closely to aerobic consumption. As a result BP reduction by suppressing noradrenaline and endothelin-1, and improving endothelial responsiveness and function [50-52]. ET also protects against oxidative stress and leads to increase in nitric oxide levels which have anti-hypertensive effects [53]. Ranković et al. [54] reported a group of patients participating in a 6-week ET program (a combination of center-based followed by home-based delivery) had C-reactive protein levels which declined by 23.7% (p < 0.001), and plasma vascular cell adhesion molecule-1 levels that decreased by 10.2% (p <0.05) when compared to the sedentary cohort.

Many patients with CHD do not have optimal levels of lipids including high density lipoprotein cholesterol (HDL-C) and triglycerides (TGs). Also, there is evidence to suggest that these patients may have improvement in these parameters with CR. Improvements may range between +6% and -15% and for HDL-C and TGs, respectively after CR. However, much better improvements have been seen in subgroups of patients who have more abnormal baseline lipid values [55-57]. Aditionally, it is common for individuals with CHD to have "isolated" low levels of HDL-C with relatively normal to borderline-elevated low-density lipoprotein levels (LDL-C) and/or TGs. These individuals are often thought to be resistant to non-pharmacological and pharmacological regimens. But, there is evidence to support prominent improvements in HDL-C (+17%) and LDL-C/HDL-C (-11%) following formal CR[58]. Although, most CHD patients with elevated LDL-C are already being treated by statin, from which they gain effective LDL-C reduction. That's why CR leads to smaller benefit among isolated LDL-C decrease [59-60].

The Effect of CR on Mortality

In the early era of CR, two pilot meta-analyses, which involved 10 to 22 randomized clinical trials and > 4000 participants revealed that ET-based CR was associated with significant reductions in all-cause and CVD mortality of ~20%-25% as compared with usual care. However, these early studies primarily included smaller trials that involved mostly middle-aged male post-MI survivors. Women and elderly populations were largely absent from the analyses, which limited the generalizability of these reports [61, 62]. In subsequent systematic reviews and meta-analyses, higher risk patients and improved methodology and reporting were employed. These demonstrated a similar reduction in mortality rates associated with CR, as high as 13%-27% for all-cause mortality and 26%-36% for CVD mortality [63-66]. A large meta-analysis of 25 randomized and non-randomized studies from 1995 onward evaluating 219,702 patients supported the benefit of CR in overall mortality reduction in patients who were post-acute coronary syndrome, post-CABG, and in mixed CHD populations [67]. In a recent Cochrane review and meta-analysis of 63 RCTs between 1970 and 2014, including 14,486 CHD patients, CR was associated with an absolute risk reduction for CVD mortality from10.4% to 7.6% with no difference in all-cause mortality [68, 69]. Another meta-analysis that only involved RCTs from 2010 to 2015 (18 trials, 7691 patients) supported the impact of supervised ET programs on CVD mortality (Hazard risk 0.58, 95% CI 0.21-0.88), but also did not find a significant effect on all-cause mortality. Interestingly, the investigators also showed that a subgroup analysis of trials involving comprehensive CR programs (i.e., ET program along with close monitoring and management of major risk factors for CHD) both all-cause and CVD mortality were significantly decreased [70]. Cardiac rehabilitation was found effective on reducing Tpe interval, Tpe/QT and Tpe/QTc which is related with ventricular arrythmia and sudden cardiac death [71].

In different group of patients, the effect of CR on all-cause and CVD mortalitysuch as stable CHD or stable angina and acute coronary syndrome, including unstable angina, ST elevation MI and non-ST elevation MI, with or without revascularization, remains unclear. A few randomized control trials (RCT) have focused on these subcategories of CHD, because of the small number of cases that are too small to studymortality effects, benefits are unclear. Studies about individuals those with impaired left ventricular function, and patients with incomplete coronary revascularization will be important in determining optimal therapy for those at high risk of decompensation and death. Aditionally, most previous studies followed patients for 12-36 months, which may not have allowed enough time to observe the associated mortality benefits from CR. As the healthcare fundings are shrinking, it will be crucial to identify the types of patients who will benefit from CR, as this will improve resource utilization in the long-term management of CVD patients [16].

Cardiac Rehabilitation and Rehospitalization

There are a little number of trials that investigated the hospital readmissions during the early studies of CR. Heran *et al.* [66] showed that total readmission rates were reduced in patients who underwent ETbased CR when compared with usual care in studies that followed patients for up to 12 months. A Cochrane review reported rehospitalization risk reduction with CR from 30.7% to 26.1% [68].Some recent trials and observational studies confirmed that, optimal medical management and early intervention may have a major impact on reducing recurrent hospitalizations in CHD and CR failed to show any benefit of CR. In contrast, the benefit of CR in reducing hospitalization has been shown for HF patients [67].

Cardiac Rehabilitation and Non-fatal Myocardial Infarction

In previous, some meta-analyses and systematic reviews did not show benefit of CR on recurrent non-

fatal MI rates [62, 64-66]. Only two meta-analyses demonstrated a reduction by 47% in non-fatal MI rates [63, 72]. A lack of benefit in the prevention of recurrent non-fatal MI in the CR group was reported by others [67, 68]. It was thought that this was due to the conversion of fatal to non-fatal MIs, thereby decreasing mortality rates once CR was incorporated into routine cardiac care.

Van Halewijn *et al.* [70] reported the reduction of MI rates by 30% in ET-based CR as compared with usual care, and that cerebrovascular events were decreased by 60%, with the number needed to treat being 45 and 82 for MI and cerebrovascular events, respectively. This study was the first to show a significant reduction in stroke rates in this population after CR; however, this may be due to more comprehensive CV care, medication optimization, and improvements in CVD risk factors, such as BP control, smoking cessation, and reduced cholesterol levels, rather than the effects of ET alone [70].

Health-related Quality of Life and Psychosocial Stress in Cardiac Rehabilitation

The role of CR in enhancing patients' wellness is related to restoring or improving functional capacity. This relates to both physical work capacity and cognitive function. The latter is important because $\sim 25\%$ of CVD events are associated withphyscosocial stress (PSS), which has been shown to be associated with prolonged hospitalization, delayed return to work, and

Table 3. Mechanisms by which moderate-to-vigorous exercise training may reduce the risk for nonfatal and fatal cardiovascular events

| Cardioprotective mechanisms of physical activity | | | | | |
|---|--|--|----------------------------------|---|--|
| Psychologic | Anti-arrhytmic | Anti-thrombotic | Anti-atherosclerotic | Hemodynamics | |
| ↑Social interactions ↓Psyhcosocial stress ↓Depression | ↑Heart rate variability ↓Adrenergic activity ↑Vagal tone | <pre>↑Fibrinolysis ↓Platelet adhesion ↓Fibrinogen ↓Blood viscosity</pre> | <pre> ↑Insulin sensitivity</pre> | ↑Cardiac remodelling ↑Coronary flow ↑EPC's and | |
| | | | | CAC'S ↓Myocardial O2 demand | |
| | | | | ↓Endothelial dysfunction | |
| | | | | ↑Nitric oxide | |

BP = blood pressure, EPCs = endothelial progenitor cells, CACs = cultured/circulating angiogenic cells, \uparrow = increased, \downarrow = decreased, O2 = oxygen. *Nitric oxide also has antithrombotic effects.

increased mortality. The effects of PSS is inversely related to health-related quality of life [73-75]. A cohort study showed a tendency to return to work earlier than those in the conventional care group [76].

Cardioprotective Effect of Cardiac Rehabilitation

A meta-analysis of CHD patients, lipid profile including total cholesterol and LDL-C levels were significantly lower in patients in the comprehensive CR group, but not the ET-only group. Another meta-analysis based on this population demonstrated reductions in total cholesterol and triglycerides, without improvements in LDL-C and HDL-C levels [64, 65]. Additionally, patients' systolic BP significantly reduced following CR. Similarly, another RCTs demonstrated significant reductions in LDL-C and systolic BP values [70]. Kasapoglu Aksoy et al. [77] found that CR was found to be effective and safe in terms of functional capacity, daily life activities and anxiety in both obese and non-obese patients. In addition, one RCT that addressed ≥ 6 CVD risk factors during CR demonstrated a reduction in overall mortality, but no differences in overall mortality were present in studies that addressed fewer risk factors. According to these findings, the improvement in CHD risk factors are closely related with concomitant medical management during the ET-based programs, suggesting a critical role of risk factor modification in the secondary prevention. The overall benefits of CR programs for CHD are summarized in Table 3 [16, 70].

Complications of Exercise Therapy

Vigorous physical exercise is a CV stressor, it it can trigger both non-fatal and fatal arrhythmias, especially in patients with known or occult CVD. The 2007 American Heart Association scientific statement on exercise and acute CVD events, the risk of any major CV complication (sudden cardiac death, total mortality or MI) is 1/60.000 - 80.000 patient-hours [78]. In a study of > 25,000 patients participating in 65 CR centers, there was one CVD event for every 8,484 exercise tests performed, one CVD event for every 50,000 patient hours of ET, and 1.3/million cardiac arrests for every patient hours of ET [79]. In a review of 4,846 CHD patients enrolled in interval and continuous CR regimens in Norway, the difference in event rates were 1 in 129,456 h of moderate ET and 1 in 23,182 h of high intensity ET [80]. Although the benefits of structured CR clearly outweigh the risks, additional data on risk stratification and prophylactic strategies (e.g., value of warm-up/cool-down, education of warning signs or symptoms) may help reduce the infrequent, ET-related CVD events. These efforts are already under-way with the development of the Physical Activity Intelligence score, a validated physiologic metric that predicts CVD and all-cause mortality based on aerobic capacity; this is discussed further elsewhere in this issue [81].

CONCLUSION

CR is a cost effective strategy in secondary prevention of CVD. CR has been widely used for over forty years n different countries worldwide, with a robust evidence. effective improvements in cardiopulmonary fitness, PSS, quality of life and reduction in morbidity and mortality. It is also a strategy for reducing hospital readmitions. Despite these evidences, CR still remain underutilized not only because of the low patient referral, but also high discontinuation rates. Further randomized controlled research is necessary to evaluate long-term outcomes to assess the persistence of change observed in supervised CR of relatively short duration. Finally, a vigilant approach to primary prevention utilizing the expertise found in CR programs is needed.

Conflict of interest

The author disclosed no conflict of interest during the preparation or publication of this manuscript.

Financing

The author disclosed that they did not receive any grant during conduction or writing of this study.

REFERENCES

[1] Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics -- 2015 update: a report from the American Heart Association. Circulation 2015;131:e29-322.

[2] Mathers CD, Loncar D. Updated projections of global mortality and burden of disease 2002-2030: Data sources, method and results. World Health Organization. 2005.

[3] Mendis S, Puska P, Norrving B. In: Mendis S,Puska P, Norrving B. eds. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland: World Health Organization 2011.

[4] Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al; PURE Investigators. Cardiovascular risk and events in 17 lowmiddle-, and high-income countries. N Engl J Med 2014;371:818-27.

[5] WHO Europe. Health for All Database (HFA-DB). WHO 2013. Web. 15 Feb. 2013, http://data.euro.who.int/hfadb/

[6] GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545-602.

[7] Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden, Am J Manag Care 2009;15:S36-S41.

[8] Anchique Santos CV, Lopez-Jimenez F, Benaim B, Burdiat G, Fernandez Coronado R, Gonzalez G, et al. Cardiac rehabilitation in Latin America. Prog Cardiovasc Dis 2014;57:268-75.

[9] Stone JA, Suskin N, Arthur HM. Canadian Guidelines for Cardiac Rehabilitation and Cardiovascular Disease Prevention: Translating Knowledge into Action, 3rd ed. Canadian Association of Cardiac Rehabilitation, Winnipeg, Manitoba, Canada, 2009.

[10] Medicare.gov.cited 2016 December 21. Available from: https:// www.medicare.gov/coverage/cardiac-rehabprograms.html

[11] McMahon SR, Ades PA, Thompson PD. The role of cardiac rehabilitation in patients with heart disease. Trends Cardiovasc Med 2017;27:420-5.

[12] Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ, et al; American Heart Association; Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention); Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); American association of Cardiovascular and Pulmonary Rehabilitation. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005;111:369-76.

[13] Balady GJ, Ades PA, Bittner VA, Franklin BA, Gordon NF, Thomas RJ, et al. Referral, enrollment and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond:a presidential advisory from the American Heart Association. Circulation 2011;124:2951-60.

[14] Wisløff U, Støylen A, Loennechen JP, Bruvold M, Rognmo Ø, Haram PM, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 2007;115:3086-94.

[15] Zwisler AD, Soja AM, Rasmussen S, Frederiksen M,

Abedini S, Appel J, et al; DANREHAB Group. Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial. Am Heart J 2008;155:1106-13.

[16] Kachur S, Chongthammakun V, Lavie CJ, De Schutter A, Arena R, Milani RV, et al. Impact of cardiac rehabilitation and exercise training programs in coronary heart disease. Prog Cardiovasc Dis 2017;60:103-14.

[17] Mampuya WM. Cardiac rehabilitation past, present and future: an overview. CardiovascDiagnTher. 2012;2:38-49.

[18] Thomas RJ, King M, Lui K, Oldridge N, Piña IL, Spertus J, et al; AACVPR; ACC; AHA; American College of Chest Physicians; American College of Sports Medicine; American Physical Therapy Association; Canadian Association of Cardiac Rehabilitation; European Association for Cardiovascular Prevention and Rehabilitation; Inter-American Heart Foundation; National Association of Clinical Nurse Specialists; Preventive Cardiovascular Nurses Association; Society of Thoracic Surgeons. AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists. Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2007;50:1400-33.

[19] Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, et al; American Heart Association Get With The Guidelines Investigators. Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program. J Am CollCardiol 2009;54:515-21.

[20] Harlan WR, Sandler SA, Lee KL, Lam LC, Mark DB. Importance of baseline functional and socioeconomic factors for participation in cardiac rehabilitation. Am J Cardiol 1995;76:36-9.

[21] Burns KJ, Camaione DN, Froman RD, Clark BA 3rd. Predictors of referral to cardiac rehabilitation and cardiac selfefficacy. Clin Nurs Res 1998;7:147-63.

[22] Ades PA, Waldmann ML, McCann WJ, Weaver SO. Predictors of cardiac rehabilitation participation in older coronary patients. Arch Intern Med 1992;152:1033-5.

[23] Grace SL, Gravely-Witte S, Brual J, Monette G, Suskin N, Higginson L, et al. Contribution of patient and physician factors to cardiac rehabilitation enrollment: a prospective multilevel study. Eur J Cardiovasc Prev Rehabil 2008;15:548-56.

[24] Barber K, Stommel M, Kroll J, Holmes-Rovner M, McIntosh B. Cardiac rehabilitation for community-based patients with myocardial infarction: factors predicting discharge recommendation and participation. Clin Epidemiol 2001;54:1025-30.

[25] Mazzini MJ, Stevens GR, Whalen D, Ozonoff A, Balady GJ. Effect of an American Heart Association Get With the Guidelines

program-based clinical pathway on referral and enrollment into cardiac rehabilitation after acute myocardial infarction. Am J Cardiol 2008;101:1084-7.

[26] Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JA, et al; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee; Council on Clinical Cardiology; Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; American Association of Cardiovascular and Pulmonary Rehabilitation. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehabil Prev 2007;27:121-9.

[27] Keteyian SJ, Hibner BA, Bronsteen K, Kerrigan D, Aldred HA, Reasons LM, et al. Greater improvement in cardiorespiratory fitness using higher-intensity interval training in the standard cardiac rehabilitation setting. J Cardiopulm Rehabil Prev 2014;34:98-105.

[28] Moholdt T, Aamot IL, Granøien I, GjerdeL, Myklebust G, Walderhaug L, et al. Aerobic interval training increases peak oxygen uptake more than usual care exercise training in myocardial infarction patients: a randomized controlled study. Clin Rehabil 2012;26:33-44.

[29] Weston M, Weston KL, Prentis JM, Snowden CP. Highintensity interval training (HIT) for effective and time-efficient pre-surgical exercise interventions. Perioper Med 2016;5:2.

[30] Liou K, Ho S, Fildes J, Ooi S-Y. High intensity interval versus moderate intensity continuous training in patients with coronary artery disease: a meta-analysis of physiological and clinical parameters. Heart Lung Circ 2016;25:166-74.

[31] MacInnis MJ, Gibala MJ. Physiological adaptations to interval training and the role of exercise intensity. J Physiol 2017;595:2915-30.

[32] Elliott AD, Rajopadhyaya K, Bentley DJ, Beltrame JF, Aromataris EC. Interval training versus continuous exercise in patients with coronary artery disease: a meta-analysis. Heart Lung Circ 2015;24:149-57.

[33] Niebauer J. Is there a role for cardiac rehabilitation after coronary artery bypass grafting? Response to Niebauer: treatment after coronary artery bypass surgery remains incomplete without rehabilitation. Circulation 2016;133:2529-37.

[34] Michaelides AP, Soulis D, Antoniades C, Antonopoulos AS, Miliou A, Ioakeimidis N, et al. Exercise duration as a determinant of vascular function and antioxidant balance in patients with coronary artery disease. Heart 2011;97:832-7.

[35] O'Keefe JH, Franklin B, Lavie CJ. Exercising for health and longevity vs peak performance: different regimens for different goals. Mayo Clin Proc 2014;89:1171-5.

[36] Williams PT, Thompson PD. Increased cardiovascular disease mortality associated with excessive exercise in heart attack survivors. Mayo Clin Proc 2014;89:1187-94.

[37] Blair SN, Kohl HW, Paffenbarger RS, Clark DG, Cooper

KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989;262:2395-401.

[38] Armstrong MEG, Green J, Reeves GK, Beral V, Cairns BJ. On behalf of the million women study collaborators*. Frequent physical activity may not reduce vascular disease risk as much as moderate activity: large prospective study of women in the United Kingdom. Circulation 2015;131:721-9.

[39] Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol 1984;56:831-8.

[40] Joyner MJ, Coyle EF. Endurance exercise performance: the physiology of champions: factors that make champions. J Physiol 2008;586:35-44.

[41] Wilson MG, Ellison GM, Cable NT. Basic science behind the cardiovascular benefits of exercise. Br J Sports Med 2016;50:93-9.

[42] Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004;364:1786-8.

[43] Schaun MI, Marschner RA, Peres TR, Markoski MM, Lehnen AM. Aerobic training prior to myocardial infarction increases cardiac GLUT4 and partially preserves heart function inspontaneously hypertensive rats. Appl Physiol Nutr Metab 2017;42:334-7.

[44] Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC, et al. The transcriptional coactivator PGC-1alphamediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci U S A 2009;106:21401-6.

[45] Soci UPR, Fernandes T, Barauna VG, Hashimoto NY, de Fátima Alves Mota G, Rosa KT, et al. Epigenetic control of exercise training-induced cardiac hypertrophy by miR-208. Clin Sci 2016;130:2005-15.

[46] Daniłowicz-Szymanowicz L, Figura-Chmielewska M, Ratkowski W, Raczak G. Effect of various forms of physical training on the autonomic nervous system activity in patients with acute myocardial infarction. Kardiol Pol 2013;71:558-65.

[47] Jørgensen RM, Abildstrøm SZ, Levitan J, Kobo R, Puzanov N, Lewkowicz M, et al. Heart rate variability density analysis (Dyx) and prediction of long-termmortality after acutemyocardial infarction. Ann Noninvasive Electrocardiol 2016;21:60-8.

[48] Hertzeanu HL, Shemesh J, Aron LA, Aron AL, Peleg E, Rosenthal T, et al. Ventricular arrhythmias in rehabilitated and nonrehabilitated post-myocardial infarction patients with left ventricular dysfunction. Am J Cardiol 1993;71:24-7.

[49] Kalupahana NS, Moustaid-Moussa N. The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms. Crit Rev Biochem Mol Biol 2012;47:379-90.

[50] Smart NA, Meyer T, Butterfield JA, Faddy SC, Passino C, Malfatto G, et al. Individual patient meta-analysis of exercise training effects on systemic brain natriuretic peptide expression in heart failure. Eur J Prev Cardiol 2012;19:428-35.

[51] Krzeminski K. The role of adrenomedullin in cardiovascular response to exercise - a review. J Hum Kinet 2016;53:127-42.

[52] Lee S, Park Y, Zhang C. Exercise training prevents coronary endothelial dysfunction in type 2 diabetic mice. Am J Biomed

Sci 2011:241-52.

[53] DeSouza CA, Shapiro LF, Clevenger CM, Dinenno FA, Monahan KD, Tanaka H, et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000;102:1351-7.

[54] Ranković G, Milicić B, Savić T, Dindić B, Mancev Z, Pesić G. Effects of physical exercise on inflammatory parameters and risk for repeated acute coronary syndrome in patients with ischemic heart disease. Vojnosanit Pregl 2009;66:44-48.

[55] Lavie CJ, Milani RV. Effects of nonpharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996;78:1286-9.

[56] Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med 2008;9:239-58.

[57] Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training on low density lipoprotein cholesterol in patients with hypertriglyceridemia and coronary artery disease. Am J Cardiol 1994;74:1192-5.

[58] Milani RV, Lavie CJ. Prevalence and effects of nonpharmacologic treatment of "isolated" low-HDL cholesterol in patients with coronary artery disease. J Cardiolpulm Rehab 1995;15:439-44.

[59] Lavie CJ, Milani RV. High-dose atorvastatin in acute coronary and cerebrovascular syndromes. J Am Coll Cardiol Intv 2010;3:340-2.

[60] Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc 2007;82:539-42.

[61] Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260:945-50.

[62] O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44.

[63] Lawler PR, Filion KB, Eisenberg MJ. Efficacy of exercisebased cardiac rehabilitation post-myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 2011;162:571-84e2.

[64] Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review andmeta-analysis of randomized controlled trials. Am J Med 2004;116:682-92.

[65] Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2000;4:CD001800.

[66] Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2011;7:CD001800.

[67] Rauch B, Davos CH, Doherty P, Saure D, Metzendorf MI, Salzwedel A, et al; 'Cardiac Rehabilitation Section', European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Heinrich-Heine University, Düsseldorf, Germany. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: a systematic reviewandmeta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prevent Cardiol 2016;23:1914-39.

[68] Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: cochrane systematic review and metaanalysis. J Am Coll Cardiol 2016;67:1-12.

[69] Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA. 1988;260:945-50.

[70] van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: a systematic review and meta-analysis. Int J Cardiol 2017;232:294-303.

[71] Vatansever Agca F, Tenekecioğlu E, Karaagac K, Topal D, Yılmaz M, Aydın O, et al. Effect of cardiac rehabilitation on Tpe interval and Tpe/QT ratio in patients with coronary artery disease. Kasmera 2016;44:148-61.

[72] Clark AM, Whelan HK, Barbour R, MacIntyre PD. A realist study of the mechanisms of cardiac rehabilitation. J Adv Nurs 2005;52:362-71.

[73] Mallik S. Patients with depressive symptoms have lower health status benefits after coronary artery bypass surgery. Circulation 2005;111:271-7.

[74] Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med 2007;120:799-806.

[75] Kachur S, Menezes AR, De Schutter A, Milani RV, Lavie CJ. Significance of comorbid psychological stress and depression on outcomes after cardiac rehabilitation. Am J Med 2016;129:1316-21.

[76] Dugmore LD, Tipson RJ, Phillips MH, Flint EJ, Stentiford NH, Bone MF, et al. Changes in cardiorespiratory fitness, psychological wellbeing, quality of life, and vocational status following a 12 month cardiac exercise rehabilitation programme. Heart 1999;81:359-66.

[77] Kasapoğlu Aksoy M, Aykurt Karlıbel İ, Arı H, Altan L. The effect of obesity on functional capacity, anxiety and daily life activities in patients with coronary artery disease and phase II cardiac rehabilitation. Eur Res J 2018;4:85-91.

[78] Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, et al; American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Heart Association Councilon Clinical Cardiology; American College of Sports Medicine. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007;115:2358-68.

[79] O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-

ACTION randomized controlled trial. JAMA 2009;301:1439-50. [80] Rognmo O, Moholdt T, Bakken H, Hole T, Mølstad P, Myhr NE, et al. Cardiovascular risk of high- versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation 2012;126:1436-40. [81] Nes BM, Gutvik CR, Lavie CJ, Nauman J, Wisløff U. Personalized activity intelligence (PAI) for prevention of cardiovascular disease and promotion of physical activity. Am J Med 2017;130:328-36.



This is an open access article distributed under the terms of Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International License.